Skip to main content
Caplight Logo









Revalesio

Revalesio

Private
Tacoma, WashingtonHealthcare & Life Scienceshttps://revalesio.com/

Last Round

VC Round

Jun 9, 2022

Total Funding Raised

$14.5M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Revalesio is a biotechnology company that develops anti-inflammatory therapeutic drugs designed to treat a variety of neurological diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

neurological therapeuticsRNS60acute ischemic strokeALS treatmentmitochondrial dysfunctionclinical stage pharmaneuroprotectionneurodegenerative diseasecytoprotective agentpharma licensingphysics-based formulationorphan drugfast track designationinflammatory modulation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Revalesio Comparables

Compare Revalesio with similar companies based on industry and business-model similarity.

Revalesio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ZZ Biotech
84%
Astrocyte Pharmaceuticals Inc.
82%
Pharmazz, Inc.
79%

Revalesio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundJun 9, 2022
VC RoundJul 22, 2020
VC RoundJun 27, 2018
GrantSep 20, 2017
VC RoundJul 5, 2016
Series B
Apr 23, 2014

Revalesio Investors

Notable investors and investment history

Revalesio investors
InvestorRounds
The ALS AssociationGrant
Northeast ALS ConsortiumGrant
ALS Finding a CureGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 22, 2026

    Monthly visitors increased 68% MoM.

  • Jul 20, 2026

    Open roles increased from 0 to 12, representing 57% of headcount.

Revalesio Filings

Explore SEC and related filing metadata, where available.

Revalesio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Revalesio's valuation, stock price, and market status.

Is Revalesio a public or private company?

Revalesio is a private company.

What is the current stock price of Revalesio?

Revalesio is a private company with no public stock price. No recent secondary market data is available.

How much is Revalesio worth (valuation)?

Valuation information for Revalesio is not publicly available.

Can I buy Revalesio stock?

Revalesio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Revalesio's last funding round?

Revalesio's most recent funding round was VC Round on June 9, 2022.

Who are the main investors in Revalesio?

Key investors in Revalesio include The ALS Association, Northeast ALS Consortium, ALS Finding a Cure.

Will Revalesio IPO soon?

No public IPO plans have been announced for Revalesio.

How can I track Revalesio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Revalesio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersTacoma, Washington
Employee Range17
Year Founded2000
Last FundingJun 9, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?